Haifa, Israel -- (SBWire) -- 06/26/2014 --Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapies, today announced it has been granted Patent No. 261087 from India's Office of the Controller General of Patents, Designs & Trade Marks for a patent titled, "Methods for Cell Expansion and Conditioned Media Produced Thereby for Therapy."
The patent, which has also been granted to Pluristem in Australia, Russia and South Africa, covers the Company's key technology platform, its method for 3-dimensional expansion of placental and adipose (fat) derived cells. It also covers the composition of cells derived using this method.
"We believe Pluristem is the global leader in the commercial-scale production of placenta-derived cells. In our manufacturing facility, we use proprietary 3-dimensional cell expansion technology that gives us the ability to precisely control cell growth based on the intended indication to be treated. Our ability to do this on a large scale is one of our key assets," stated Pluristem CEO Zami Aberman.
"This patent issued by India is an important part of our global IP strategy to protect our breakthrough cell production methods in high-value and emerging healthcare markets where we see future potential for growth," Aberman added.
About Pluristem Therapeutics
Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapies. The Company's patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the Company's proprietary 3D micro-environmental technology and are an "off-the-shelf" product that requires no tissue matching prior to administration.
Pluristem has a strong intellectual property position, Company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. For more information visit http://www.pluristem.com, the content of which is not part of this press release.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, we are using forward-looking statements, when we discuss being a global leader in the commercial-scale production of placenta-derived cells, or our ability to precisely control cell growth based on the intended indication to be treated and do it on a large scale. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.
Pluristem Receives Patent in India for Cell Therapy Production Methods and Compositions